ClinicalTrials.gg
CompletedNCT02614547Updated Sep 15, 2025Results posted

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

A Phase 2 interventional study of SAGE-547 and Placebo in Severe Postpartum Depression, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.

Enrollment
170th of 198
21 · median 86
Started
2015
with 7 others
Phase 2
18 of 220
none open now
Registered
71st of 220
by date
Lead sponsor
6 of 220
Supernus Pharmaceuticals, Inc.

Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 170th largest by enrollment of the 198 interventional ones that give a count, is one of 8 that started in 2015, is one of 18 in phase 2, and was the 71st registered.

Depression, Postpartum

569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Depression, Postpartum with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression.

03

Conditions studied

  • Severe Postpartum Depression
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant either must have ceased lactating at Screening; or if still lactating at Screening, must have already fully and permanently weaned their infant(s) from breastmilk; or if still actively breastfeeding at Screening, must agree to cease giving breastmilk to their infant(s) prior to receiving study drug.
  • Participant had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Axis I Disorders (SCID-I).
  • Participant was less than or equal to (\<=) six months postpartum.
  • Participant must be amenable to intravenous therapy.

Key Exclusion Criteria:

  • Active psychosis.
  • Attempted suicide associated with index case of postpartum depression.
  • Medical history of seizures.
  • Medical history of bipolar disorder.

Note: suicidal ideation was not an exclusion. Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received infusion rates of placebo matched to SAGE-547.

    Drug: Placebo

  • Experimental
    SAGE-547

    Participants received a 4-hour dose titration of 30 micrograms per kilogram per hour (micrograms/kg/hr) (0 to 4 hours), then 60 micrograms/kg/hr (4 to 24 hours), then 90 micrograms/kg/hr (24 to 52 hours), followed by a taper to 60 micrograms/kg/hr (52 to 56 hours), and 30 micrograms/kg/hr (56 to 60 hours).

    Drug: SAGE-547

Interventions

  • Administered as intravenous infusion.

  • DrugPlacebo

    Administered as intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline at End of Treatment Period (at 60 Hours) in Hamilton Rating Scale for Depression (HAM-D) Total Score

    The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline, 60 Hours

Secondary outcomes

  1. Percentage of Participants With HAM-D Response

    The HAM-D response was defined as having a 50 percent (%) or greater reduction from baseline in HAM-D total score. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: 60 Hours, Days 7 and 30

  2. Percentage of Participants With HAM-D Remission

    The HAM-D remission was defined as having a HAM-D total score of less than or equal to (\<=)7. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: 60 Hours, Days 7, and 30

  3. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicate more severe depression. A negative change from baseline indicate less severe depression. A positive change from baseline indicates more severe depression.

    Time frame: Baseline, 60 Hours, Days 7 and 30

  4. Percentage of Participants With Clinical Global Impression-Improvement (CGI-I) Response

    The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments, and by definition, was evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of "very much improved" or "much improved".

    Time frame: 60 Hours, Days 7 and 30

  5. Change From Baseline in HAM-D Bech 6 Subscale

    The HAM-D Bech 6 subscale score was calculated as the sum of the following six items: depressed mood, feelings of guilt, work and activities, retardation, psychic anxiety, and general somatic symptoms. Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a scale of 0 to 100, with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline, 60 Hours, Days 7 and 30

  6. Change From Baseline to 60 Hours in the HAM-D Individual Item Scores

    The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline, 60 Hours

  7. Change From Baseline in Generalized Anxiety Disorder 7-item Scale (GAD-7) Total Score

    The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = "not at all sure," 1 = "several days," 2 = "over half the days," and 3 = "nearly every day" to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety.

    Time frame: Baseline, 60 Hours, Day 7 and 30

  8. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.

    Time frame: Up to 30 days

07

Results

Posted Sep 13, 2021

Participant flow

Participants took part in the study at 4 centers in the United States from 15 December 2015 to 22 June 2016.

Participant flow — Overall Study
MilestonePlaceboSAGE-547
Started1110
Completed1110
Not completed00

Outcome measures

PrimaryChange From Baseline at End of Treatment Period (at 60 Hours) in Hamilton Rating Scale for Depression (HAM-D) Total Score

The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Baseline, 60 Hours
Reported as:
Least squares mean · score on a scale
Change From Baseline at End of Treatment Period (at 60 Hours) in Hamilton Rating Scale for Depression (HAM-D) Total Score
score on a scalePlaceboSAGE-547
Change From Baseline at End of Treatment Period (at 60 Hours) in Hamilton Rating Scale for Depression (HAM-D) Total Score-8.75 ± 2.800-20.97 ± 2.938
Statistical analysis
  • Placebo vs SAGE-547 · MMRM · p = 0.008 · Least squares mean difference: -12.22 · 95% CI -20.77 to -3.67
SecondaryPercentage of Participants With HAM-D Response

The HAM-D response was defined as having a 50 percent (%) or greater reduction from baseline in HAM-D total score. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
60 Hours, Days 7 and 30
Reported as:
Number · percentage of participants
Percentage of Participants With HAM-D Response
percentage of participantsPlaceboSAGE-547
60 Hours36.470.0
Day 720.080.0
Day 3027.370.0
Statistical analysis
  • Placebo vs SAGE-547 · Fisher Exact · p = 0.198 · Odds ratio (or): 4.08 · 95% CI 0.49 to 37.67
  • Placebo vs SAGE-547 · Fisher Exact · p = 0.023 · Odds ratio (or): 16.00 · 95% CI 1.31 to 239.57
  • Placebo vs SAGE-547 · Fisher Exact · p = 0.086 · Odds ratio (or): 6.22 · 95% CI 0.70 to 62.08
SecondaryPercentage of Participants With HAM-D Remission

The HAM-D remission was defined as having a HAM-D total score of less than or equal to (\<=)7. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
60 Hours, Days 7, and 30
Reported as:
Number · percentage of participants
Percentage of Participants With HAM-D Remission
percentage of participantsPlaceboSAGE-547
60 Hours9.170.0
Day 70.070.0
Day 3018.270.0
Statistical analysis
  • Placebo vs SAGE-547 · Fisher Exact · p = 0.008 · Odds ratio (or): 23.33 · 95% CI 1.56 to 1152.71
  • Placebo vs SAGE-547 · Fisher Exact · p = 0.003
  • Placebo vs SAGE-547 · Fisher Exact · p = 0.030 · Odds ratio (or): 10.50 · 95% CI 1.01 to 140.57
SecondaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicate more severe depression. A negative change from baseline indicate less severe depression. A positive change from baseline indicates more severe depression.

Time frame:
Baseline, 60 Hours, Days 7 and 30
Reported as:
Least squares mean · score on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
score on a scalePlaceboSAGE-547
Hour 60-12.10 ± 3.817-27.96 ± 4.001
Day 7-11.60 ± 3.766-27.56 ± 3.929
Day 30-11.19 ± 3.594-26.26 ± 3.767
Statistical analysis
  • Placebo vs SAGE-547 · MMRM · p = 0.010 · Least squares mean difference: -15.86 · 95% CI -27.50 to -4.22
  • Placebo vs SAGE-547 · MMRM · p = 0.009 · Least square mean difference: -15.96 · 95% CI -27.43 to -4.50
  • Placebo vs SAGE-547 · MMRM · p = 0.010 · Least square mean difference: -15.07 · 95% CI -26.05 to -4.09
SecondaryPercentage of Participants With Clinical Global Impression-Improvement (CGI-I) Response

The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments, and by definition, was evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of "very much improved" or "much improved".

Time frame:
60 Hours, Days 7 and 30
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Global Impression-Improvement (CGI-I) Response
percentage of participantsPlaceboSAGE-547
Hour 6036.480.0
Day 720.080.0
Day 3027.380.0
Statistical analysis
  • Placebo vs SAGE-547 · Fisher Exact · p = 0.080 · Odds ratio (or): 7.00 · 95% CI 0.73 to 90.81
  • Placebo vs SAGE-547 · Fisher Exact · p = 0.023 · Odds ratio (or): 16.00 · 95% CI 1.31 to 239.57
  • Placebo vs SAGE-547 · Fisher Exact · p = 0.030 · Odds ratio (or): 10.67 · 95% CI 1.04 to 142.20
SecondaryChange From Baseline in HAM-D Bech 6 Subscale

The HAM-D Bech 6 subscale score was calculated as the sum of the following six items: depressed mood, feelings of guilt, work and activities, retardation, psychic anxiety, and general somatic symptoms. Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a scale of 0 to 100, with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Baseline, 60 Hours, Days 7 and 30
Reported as:
Least squares mean · score on a scale
Change From Baseline in HAM-D Bech 6 Subscale
score on a scalePlaceboSAGE-547
60 Hours-4.89 ± 1.701-10.94 ± 1.784
Day 7-3.99 ± 1.676-10.44 ± 1.754
Day 30-3.34 ± 1.772-10.14 ± 1.858
Statistical analysis
  • Placebo vs SAGE-547 · MMRM · p = 0.025 · Least squares mean difference: -6.05 · 95% CI -11.24 to -0.86
  • Placebo vs SAGE-547 · MMRM · p = 0.016 · Least squares mean difference: -6.46 · 95% CI -11.57 to -1.34
  • Placebo vs SAGE-547 · MMRM · p = 0.018 · Least squares mean difference: -6.80 · 95% CI -12.25 to -1.35
SecondaryChange From Baseline to 60 Hours in the HAM-D Individual Item Scores

The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Baseline, 60 Hours
Reported as:
Mean · score on a scale
Change From Baseline to 60 Hours in the HAM-D Individual Item Scores
score on a scalePlaceboSAGE-547
Depressed Mood, Change From Baseline to 60 Hours-1.4 ± 1.57-2.5 ± 1.58
Feeling of Guilt ,Change From Baseline to 60 Hours-0.5 ± 0.69-1.7 ± 0.95
Suicide, Change From Baseline to 60 Hours-0.4 ± 0.67-1.1 ± 0.88
Insomnia - Early, Change From Baseline to 60 Hours-0.5 ± 0.69-1.6 ± 0.70
Insomnia -Middle, Change From Baseline to 60 Hours-0.5 ± 0.69-1.6 ± 0.52
Insomnia - Late, Change From Baseline to 60 Hours-0.4 ± 0.50-1.1 ± 0.74
Work and Activities, Change From Baseline to 60 Hours-1.4 ± 1.36-2.4 ± 1.35
Retardation, Change From Baseline to 60 Hours-0.5 ± 0.69-0.8 ± 0.79
Agitation, Change From Baseline to 60 Hours-0.3 ± 0.65-0.3 ± 0.67
Anxiety-Psychic, Change From Baseline to 60 Hours-0.9 ± 1.30-1.9 ± 1.29
Anxiety-Somatic, Change From Baseline to 60 Hours-1.0 ± 1.10-1.9 ± 1.66
Gastrointestinal, Change From Baseline to 60 Hours-0.4 ± 0.81-0.7 ± 0.95
Somatic General, Change From Baseline to 60 Hours-0.4 ± 0.67-1.5 ± 0.85
Genital Symptoms, Change From Baseline to 60 Hours-0.2 ± 0.60-0.8 ± 0.79
Hypochondriasis, Change From Baseline to 60 Hours-0.3 ± 1.19-0.5 ± 0.71
Loss of Weight, Change From Baseline to 60 Hours-0.4 ± 0.67-0.2 ± 0.67
Insight, Change From Baseline to 60 Hours0.0 ± 0.000.0 ± 0.00
SecondaryChange From Baseline in Generalized Anxiety Disorder 7-item Scale (GAD-7) Total Score

The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = "not at all sure," 1 = "several days," 2 = "over half the days," and 3 = "nearly every day" to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety.

Time frame:
Baseline, 60 Hours, Day 7 and 30
Reported as:
Least squares mean · score on a scale
Change From Baseline in Generalized Anxiety Disorder 7-item Scale (GAD-7) Total Score
score on a scalePlaceboSAGE-547
60 Hours-9.08 ± 1.673-7.21 ± 1.757
Day 7-7.96 ± 1.986-9.44 ± 1.986
Day 30-7.38 ± 1.951-9.48 ± 2.050
Statistical analysis
  • Placebo vs SAGE-547 · ANCOVA · p = 0.457 · Least squares mean difference: 1.87 · 95% CI -3.30 to 7.04
  • Placebo vs SAGE-547 · ANCOVA · p = 0.613 · Least square mean: -1.47 · 95% CI -7.50 to 4.55
  • Placebo vs SAGE-547 · ANCOVA · p = 0.474 · Least square mean: -2.10 · 95% CI -8.13 to 3.93
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.

Time frame:
Up to 30 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboSAGE-547
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)84

Adverse events

Collected over Up to 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/11 (0%)0/11 (0%)8/11 (72.7%)
SAGE-5470/10 (0%)0/10 (0%)4/10 (40%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlaceboSAGE-547
DizzinessNervous system disorders3/112/10
NauseaGastrointestinal disorders3/111/10
SomnolenceNervous system disorders0/112/10
Abnormal dreamsPsychiatric disorders2/110/10
HeadacheNervous system disorders2/110/10
InsomniaPsychiatric disorders2/110/10
Infusion Site PainGeneral disorders2/110/10
Dizziness posturalNervous system disorders0/111/10
SedationNervous system disorders0/111/10
Sinus TachycardiaCardiac disorders0/111/10

Baseline characteristics

All randomized population included the subset of participants from all enrolled population who were randomized.

Age, Continuous
Age, Continuous(years)PlaceboSAGE-547Total
Mean28.8 ± 4.5827.4 ± 5.3428.1 ± 4.88
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSAGE-547Total
Female111021
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboSAGE-547Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American6713
White538
More than one race000
Unknown or Not Reported000
08

Study locations

4 sites
  • Sage Investigational Site
    Atlanta, Georgia 30342, United States
  • Sage Investigational Site
    Worcester, Massachusetts 01655, United States
  • Sage Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • Sage Investigational Site
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Gerbasi ME, Meltzer-Brody S, Acaster S, Fridman M, Bonthapally V, Hodgkins P, Kanes SJ, Eldar-Lissai A. Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making. J Womens Health (Larchmt). 2021 Mar;30(3):385-392. doi: 10.1089/jwh.2020.8483. Epub 2020 Nov 12. PubMed 33181049 ↗
  • Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenberg R, Hoffmann E, Rubinow D, Jonas J, Paul S, Meltzer-Brody S. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017 Jul 29;390(10093):480-489. doi: 10.1016/S0140-6736(17)31264-3. Epub 2017 Jun 12. PubMed 28619476 ↗

Related links

Individual participant data

Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Jun 2016, 6 months.

Results were first posted in Sep 2021, 5 years 2 months after primary completion. A results delay was requested in Aug 2017.

Of 14 phase 2 interventional studies under Depression, Postpartum, half reached primary completion within 17 months of starting (the median); a quarter within 10 and three quarters within 30. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2015
First posted
Nov 25, 2015
StartActual
Dec 15, 2015
Primary completionActual
Jun 22, 2016
CompletionActual
Jun 22, 2016
Results delay requested
Aug 4, 2017
Results first posted
Sep 13, 2021
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02614547
Responsible party
Sponsor
First posted
Nov 25, 2015
Start date
Dec 15, 2015
Primary completion
Jun 22, 2016
Completion
Jun 22, 2016
Results posted
Sep 13, 2021
Last update
Sep 15, 2025

Study contacts

Stephen J Kanes, MD, PhD
study chair · Sage Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexanolone

Start the discussion